<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053559</url>
  </required_header>
  <id_info>
    <org_study_id>Exempt IND</org_study_id>
    <nct_id>NCT01053559</nct_id>
  </id_info>
  <brief_title>Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy</brief_title>
  <official_title>Open Label Investigator Initiated, Single Site Study of Mucosal Healing in Patients With Small Bowel Crohn's Disease Treated With Certolizumab Pegol (Cimzia) Assessed by Wireless Capsule Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shafran Gastroenterology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shafran Gastroenterology Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Wireless Capsule Endoscopy has been the most reliable diagnostic standard for small bowel
      Crohn's disease. Endoscopic healing is an important endpoint to measure response to
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mucosal Healing</measure>
    <time_frame>180 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP) Level</measure>
    <time_frame>180 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>certolizumab pegol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will receive FDA approved Cimzia injections as indicated on the product label. Subjects will undergo 3 wireless capsule endoscopies, one at screening,Day 84 and Day 168 as well as monthly bloodwork.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>certolizumab pegol</intervention_name>
    <description>400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter</description>
    <arm_group_label>certolizumab pegol</arm_group_label>
    <other_name>Cimzia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 18-70 with confirmed Crohn's disease that includes small bowel disease

          -  Moderately to severely active disease (CDAI score &gt;220 and &lt; 450)

          -  Stable doses of steroids, 5-ASA, antibiotics, Immunosuppressants

        Exclusion Criteria:

          -  Any and all contraindications to the use of certolizumab pegol (including but not
             limited to hepatitis, infection, abscess, malignancy, congestive heart failure [CHF],
             cytopenia)

          -  Small bowel obstruction, stricture, or any contraindication for capsule endoscopy

          -  Previous treatment with certolizumab pegol

          -  Are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ira Shafran, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shafran Gastroenterology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shafran Gastroenterology Center</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.shafran.net</url>
    <description>Practice Website</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>April 23, 2014</last_update_submitted>
  <last_update_submitted_qc>April 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shafran Gastroenterology Center</investigator_affiliation>
    <investigator_full_name>Ira Shafran M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Crohn's</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 20, 2016</submitted>
    <returned>May 26, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

